Last Updated: November 16, 2026

Investigational Drug Information for SEP-363856

« Back to Dashboard


What is the drug development status for SEP-363856?

SEP-363856 is an investigational drug.

There have been 28 clinical trials for SEP-363856. The most recent clinical trial was a Phase 2 trial, which was initiated on February 25th 2025.

The most common disease conditions in clinical trials are Schizophrenia, Disease, and Psychotic Disorders. The leading clinical trial sponsors are Sunovion, Sumitomo Dainippon Pharma Co., Ltd., and Sumitomo Pharma Co., Ltd.

There are zero US patents protecting this investigational drug and zero international patents.

Recent Clinical Trials for SEP-363856
TitleSponsorPhase
A Long-term Administration Trial of SEP-363856 in Patients With SchizophreniaOtsuka Pharmaceutical Co., Ltd.PHASE3
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With SchizophreniaOtsuka Pharmaceutical Development & Commercialization, Inc.PHASE3
A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With SchizophreniaSunovionPhase 1

See all SEP-363856 clinical trials

Clinical Trial Summary for SEP-363856

Top disease conditions for SEP-363856
Top clinical trial sponsors for SEP-363856

See all SEP-363856 clinical trials

US Patents for SEP-363856

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
SEP-363856 ⤷  Start Trial Bisarylsulfonamides useful in the treatment of inflammation and cancer Kancera AB ⤷  Start Trial
SEP-363856 ⤷  Start Trial Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors Novartis AG ⤷  Start Trial
SEP-363856 ⤷  Start Trial Substituted indole Mcl-1 inhibitors Vanderbilt University (Nashville, TN) ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

SEP-363856 (Ulotaront) Development Update and Market Projection

Last updated: November 9, 2026

SEP-363856, also known as ulotaront, is an investigational oral antipsychotic developed by Sumitomo Pharma through its U.S. subsidiary Sunovion Pharmaceuticals. The drug is a trace amine-associated receptor 1, or TAAR1, agonist with additional 5-HT1A activity. It was designed to treat schizophrenia without direct dopamine D2 receptor antagonism.

Ulotaront produced positive Phase 2 results, received FDA Breakthrough Therapy designation, and entered a global Phase 3 program. The pivotal program later failed to establish efficacy consistently against placebo. No FDA approval, commercial launch, Orange Book listing, or FDA-recognized regulatory exclusivity period has been established for SEP-363856. Its commercial outlook is therefore materially weaker than the early clinical data suggested.

What is the current development status of SEP-363856?

The latest publicly documented development status is that ulotaront has not advanced to FDA approval and has no established commercial launch date.

Development item Status
Active ingredient Ulotaront, SEP-363856
Developer Sumitomo Pharma; previously Sunovion Pharmaceuticals
Pharmacology TAAR1 agonist with 5-HT1A activity
Lead indication Schizophrenia
FDA designation Breakthrough Therapy designation granted in 2019
Phase 2 Positive results reported
Phase 3 Pivotal studies failed to demonstrate a reliable efficacy advantage
FDA filing No publicly confirmed NDA approval
Commercial status Not marketed
Orange Book No approved-product listing
Biosimilar status Not applicable; ulotaront is a small molecule
Main development risk Reproducibility of antipsychotic efficacy in Phase 3

The Phase 2 study enrolled adults with an acute exacerbation of schizophrenia. Ulotaront reduced Positive and Negative Syndrome Scale, or PANSS, scores more than placebo over six weeks. The least-squares mean change was approximately -17.2 points for ulotaront versus -9.7 points for placebo, with a reported p-value of 0.001. The study also reported relatively low rates of weight gain, akathisia, extrapyramidal symptoms, and prolactin elevation compared with conventional antipsychotics. (Koblan et al., 2020)

The result supported Breakthrough Therapy designation and justified advancement into the DIAMOND Phase 3 program. Breakthrough designation accelerated interactions with FDA but did not guarantee approval or reduce the requirement to demonstrate efficacy in adequate and well-controlled trials.

Why did the SEP-363856 Phase 3 program fail?

The principal issue was failure to reproduce the Phase 2 efficacy signal in the pivotal schizophrenia studies.

Sumitomo Pharma evaluated ulotaront in the DIAMOND-1 and DIAMOND-2 Phase 3 trials. The studies were designed to assess improvement in PANSS total score in patients with acute schizophrenia. Publicly reported results indicated that the program did not meet its primary efficacy objectives consistently enough to support an application based on the available data.

The clinical interpretation is significant:

  1. The TAAR1 mechanism remains pharmacologically differentiated.
  2. The Phase 2 efficacy signal was not sufficient to establish regulatory confidence.
  3. Safety and tolerability advantages cannot compensate for failure on the primary efficacy endpoint.
  4. A new confirmatory Phase 3 program would be expensive and would require a clear rationale for correcting the earlier outcome.

A failed Phase 3 program usually reduces the probability of approval sharply, particularly for a psychiatric drug competing against inexpensive generic antipsychotics and newer branded agents with demonstrated efficacy.

What is the FDA regulatory status of ulotaront?

Ulotaront is not FDA-approved for schizophrenia or any other condition.

The drug received FDA Breakthrough Therapy designation in 2019 based on preliminary clinical evidence indicating a substantial improvement over available therapy on one or more clinically significant endpoints. The designation provided regulatory support, but it did not establish approval eligibility.

There is no publicly confirmed:

  • New Drug Application approval
  • Prescription drug labeling
  • FDA postmarketing requirement
  • Orange Book patent listing
  • FDA regulatory exclusivity period
  • Approved dosage or administration schedule

If development were restarted and an NDA were approved, ulotaront could potentially receive five years of new chemical entity exclusivity, subject to FDA classification and applicable statutory rules. That protection would apply only after approval and would not replace patent protection.

What patents protect SEP-363856?

SEP-363856 is associated with proprietary small-molecule chemistry and development know-how held through the Sumitomo Pharma and Sunovion organization. Publicly available patent records indicate that protection has been pursued around the compound class, pharmaceutical compositions, and therapeutic use.

The commercially relevant patent categories are likely to include:

Patent category Commercial purpose
Composition-of-matter patents Protect ulotaront and related chemical entities
Salt and solid-form patents Protect crystalline, amorphous, or pharmaceutically acceptable forms
Pharmaceutical-composition patents Cover tablets, capsules, excipients, and dosage forms
Method-of-treatment patents Cover treatment of schizophrenia and related psychiatric disorders
Manufacturing patents Protect synthesis, intermediates, purification, and scale-up processes
Combination patents Potentially cover use with other psychiatric medicines

No Orange Book-listed patent exists because no ulotaront product has FDA approval. Accordingly, there is no current Orange Book Paragraph IV pathway specifically tied to SEP-363856.

The likely patent-life issue is less important than the clinical status. Even if composition-of-matter protection extends into the late 2020s or early 2030s, the absence of approval and the failed Phase 3 program limit its present economic value. Patent expiration cannot create a market for a product that has not demonstrated an approvable benefit-risk profile.

When does SEP-363856 lose exclusivity?

There is no FDA-assigned exclusivity-loss date because ulotaront has not been approved.

Any meaningful exclusivity timeline would depend on three events:

  1. Resumption of clinical development.
  2. Submission and approval of an NDA.
  3. Confirmation of surviving patent claims and their terminal-disclaimer status.

The relevant protection periods would include patent term, potential five-year new chemical entity exclusivity, possible three-year exclusivity for certain supplemental clinical investigations, and any pediatric exclusivity. None of these FDA exclusivity periods is active today.

Patent-based protection could still matter if Sumitomo Pharma restarts the program and obtains approval, but the precise expiry date cannot be treated as a commercial milestone without identifying the issued U.S. patents that claim ulotaront itself and confirming any patent-term adjustment.

Are there Paragraph IV challenges or generic launch risks?

No public Paragraph IV litigation or generic challenge is associated with ulotaront because the drug is not an approved U.S. product.

A generic launch scenario would require:

  • FDA approval of ulotaront or an equivalent reference product.
  • An approved reference listed drug.
  • A future abbreviated new drug application.
  • Resolution of any valid composition, formulation, or method-of-use patents.
  • Demonstration of pharmaceutical equivalence and bioequivalence.

The near-term risk is therefore not generic entry. The more immediate risk is abandonment or prolonged development delay. If the product were eventually approved, generic erosion would likely be rapid after core patent expiry because schizophrenia treatment is heavily exposed to low-cost generic alternatives.

What formulations are protected by SEP-363856 patents?

No FDA-approved ulotaront formulation is commercially available. Clinical development used oral administration, but the final market formulation has not been established through an approved label.

Potential formulation protection could cover:

  • Immediate-release oral tablets
  • Solid oral dosage forms
  • Specific particle sizes or polymorphs
  • Stability-enhancing excipient systems
  • Modified-release dosage forms
  • Unit-dose packaging
  • Manufacturing processes that improve purity or yield

Formulation patents would have limited standalone value unless they prevented substitution with a therapeutically equivalent product. For a conventional oral tablet, composition-of-matter claims generally carry more commercial weight than routine formulation claims.

What patent litigation affects SEP-363856?

No major public U.S. patent litigation involving ulotaront has been established. There is also no known ANDA litigation record comparable to disputes involving approved branded antipsychotics.

The absence of litigation reflects the drug's development stage rather than a demonstrated absence of patent risk. If the program were revived, likely disputes would involve:

  • Validity of composition-of-matter claims
  • Obviousness of TAAR1 agonist structures
  • Written-description and enablement requirements
  • Infringement by generic therapeutic-use claims
  • Ownership of discoveries made under the Sunovion-PsychoGenics collaboration
  • Patent-term adjustment and terminal disclaimers

How does ulotaront compare with competing antipsychotics?

Ulotaront's main proposed advantage is mechanism and tolerability rather than established efficacy.

Drug or class Mechanism Market status Key commercial strength Main weakness
Ulotaront TAAR1 agonist; 5-HT1A activity Investigational Potentially lower metabolic and motor burden Failed pivotal efficacy program
Aripiprazole Partial D2/D3 agonist Approved; largely generic Broad indications and established use Akathisia and impulse-control concerns
Cariprazine D2/D3 partial agonist Approved Bipolar and schizophrenia positioning Akathisia; branded pricing pressure
Lumateperone Serotonin-dopamine modulator Approved Schizophrenia and bipolar indications Commercial competition and tolerability tradeoffs
Olanzapine D2/5-HT2A antagonist Generic Strong efficacy and low cost Weight gain and metabolic effects
Quetiapine D2/5-HT2A antagonist Generic Broad psychiatric use Sedation and metabolic effects
Xanomeline/trospium Muscarinic agonist/antagonist combination Approved in 2024 as Cobenfy Non-D2 mechanism Gastrointestinal, cardiovascular, and administration burdens

Ulotaront would need to demonstrate both clinically meaningful efficacy and a clearly better tolerability profile to compete with generic antipsychotics. A novel mechanism alone would not support premium pricing.

Which companies are challenging or competing with ulotaront?

No company is publicly challenging ulotaront through an ANDA or biosimilar pathway. The competitive field consists of marketed antipsychotic products and other pipeline therapies.

The principal competitive groups are:

  • Bristol Myers Squibb, through Cobenfy after its acquisition of Karuna Therapeutics
  • AbbVie, through Vraylar, formerly developed by Allergan and Forest Laboratories
  • Sumitomo Pharma, through Latuda and its broader CNS portfolio
  • Intra-Cellular Therapies, through Caplyta
  • Otsuka Pharmaceutical, through Abilify and related products
  • Generic manufacturers supplying risperidone, olanzapine, quetiapine, aripiprazole, and other agents

Cobenfy is the most relevant newer mechanistic comparator because it entered the market with a non-D2 approach. Its approval increases the evidentiary and commercial standard for a future TAAR1-based schizophrenia product.

What is the market projection for SEP-363856?

The base-case commercial projection is zero near-term revenue because ulotaront has no approval or launch. A restart scenario could produce a meaningful product, but probability-adjusted value is substantially below the value implied by the early Phase 2 data.

Scenario analysis

Scenario Development assumption Potential peak global sales Probability-adjusted commercial view
Base case Program remains inactive or discontinued $0 Dominant scenario
Restart, limited indication New Phase 3 program succeeds in schizophrenia only $300 million-$700 million Low probability
Successful differentiated launch Efficacy and tolerability support premium positioning $800 million-$1.5 billion Very low probability
Broad CNS expansion Schizophrenia plus bipolar disorder or other psychosis indications $1.5 billion-$2.5 billion Speculative

These estimates assume a branded oral product, U.S., European, and Japanese commercialization, and pricing above generic antipsychotics. They do not represent reported company guidance.

A realistic launch would face several constraints:

  • High failure risk after the Phase 3 results.
  • Generic competition in every major schizophrenia market.
  • Need for payer evidence showing lower hospitalization, better adherence, or lower adverse-event costs.
  • Competition from Cobenfy and other non-D2 mechanisms.
  • Limited differentiation if ulotaront improves tolerability but not efficacy.
  • Large clinical-trial costs for a replacement pivotal program.
  • Need to establish long-term safety in a chronic-use population.

A successful product could generate significant revenue if it reduced weight gain, extrapyramidal symptoms, hyperprolactinemia, and sedation without sacrificing efficacy. The commercial opportunity would be strongest among patients who discontinue existing antipsychotics because of metabolic or motor adverse events.

How strong is the SEP-363856 patent estate?

The patent estate has theoretical value but low current commercial strength.

Factor Assessment
Mechanism differentiation Strong
Phase 2 clinical signal Positive
Phase 3 validation Weak after pivotal failure
FDA status No approval
Orange Book position None
Generic exposure Deferred, not eliminated
Formulation value Unproven
Manufacturing barrier Potentially meaningful but unlikely to offset efficacy risk
Licensing value Limited without a credible clinical recovery plan
Overall asset strength Low to moderate scientifically; low commercially

Manufacturing complexity could create a barrier if the compound requires difficult chiral synthesis, specialized intermediates, or demanding impurity controls. Those barriers would support supply security but would not prevent competition after approval if the composition-of-matter claims expired or were invalidated.

Are there licensing deals involving SEP-363856?

Ulotaront originated from work involving Sunovion and PsychoGenics. The program was advanced within the Sumitomo Pharma organization after Sumitomo acquired Sunovion's parent company.

No major third-party licensing transaction establishing a new commercial partner for ulotaront has been publicly confirmed. The absence of a large licensing deal is consistent with the drug's unresolved Phase 3 efficacy profile.

A future transaction would likely depend on one of three developments:

  • A convincing reanalysis of the failed trials.
  • New data identifying a responsive patient subgroup.
  • Positive evidence in another indication, such as bipolar disorder or Parkinson's disease psychosis.

What generic launch scenarios exist for ulotaront?

There is no immediate generic launch scenario. If the drug were approved, three pathways would matter.

Early patent challenge

A generic manufacturer could file an ANDA with a Paragraph IV certification against listed patents. Litigation could delay approval for up to 30 months under the Hatch-Waxman framework, subject to statutory exceptions.

Post-core-patent entry

Generic entry after composition-of-matter expiry would likely cause rapid price erosion. Schizophrenia treatment has extensive generic substitution, and payers generally favor low-cost oral antipsychotics.

Formulation-only protection

If only formulation or method-of-use patents survived, an authorized generic or alternative formulation could weaken market protection. Ulotaront would need broad claims covering the active compound to preserve a durable premium market.

Key Takeaways

  • SEP-363856, or ulotaront, is an investigational TAAR1 agonist developed by Sumitomo Pharma and Sunovion.
  • Phase 2 schizophrenia data were positive, but the Phase 3 DIAMOND program did not establish a reliable efficacy benefit.
  • The drug has no FDA approval, commercial product, Orange Book listing, or active regulatory exclusivity period.
  • No public Paragraph IV challenge or ANDA litigation is associated with ulotaront.
  • Patent protection may exist around the compound, formulations, therapeutic uses, and manufacturing, but patent value is constrained by the failed pivotal program.
  • Near-term revenue is expected to be zero absent a development restart.
  • A successful relaunch could support peak global sales of roughly $300 million to $1.5 billion, but the probability of reaching that outcome is low.
  • The strongest commercial opportunity would be a differentiated schizophrenia product with proven efficacy and materially lower metabolic, motor, and prolactin-related adverse effects.

FAQs

Is SEP-363856 the same drug as ulotaront?

Yes. SEP-363856 is the development code for ulotaront, an investigational TAAR1 agonist with 5-HT1A activity.

Has ulotaront been approved by the FDA?

No. Ulotaront has not received FDA approval for schizophrenia or another indication.

Does ulotaront have an Orange Book patent?

No approved ulotaront product appears in the FDA Orange Book, so there is no current Orange Book patent listing for the drug.

Could ulotaront be developed for bipolar disorder?

Potentially, but no successful regulatory path for bipolar disorder has been established. A new indication would require supportive clinical trials and a separate benefit-risk assessment.

What is the main investment risk for SEP-363856?

The central risk is clinical rather than patent-related. The pivotal schizophrenia program failed to confirm the Phase 2 efficacy signal, leaving the asset without a demonstrated path to approval or revenue.

References

  1. Koblan, K. S., Kent, J., Hopkins, S. C., Krystal, J. H., Walling, D. P., Warren, C., Xi, L., Lykens, K., O'Neill, J., & Drevets, W. C. (2020). A non-D2-receptor-binding drug for the treatment of schizophrenia. New England Journal of Medicine, 382(16), 1497-1506. https://doi.org/10.1056/NEJMoa1911773

  2. ClinicalTrials.gov. (n.d.). Study of SEP-363856 in subjects with an acute exacerbation of schizophrenia: DIAMOND 1. U.S. National Library of Medicine. https://clinicaltrials.gov/

  3. ClinicalTrials.gov. (n.d.). Study of SEP-363856 in subjects with an acute exacerbation of schizophrenia: DIAMOND 2. U.S. National Library of Medicine. https://clinicaltrials.gov/

  4. U.S. Food and Drug Administration. (2019). FDA grants Breakthrough Therapy designation to SEP-363856 for the treatment of schizophrenia. FDA.

  5. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.